Oncko
10 employees on LinkedIn · 3 known investors
Find your way into Oncko
991 people in our graph share verified history with the Oncko team — schools, employers, funds. One of them is your warm intro.
Anika Guptaunlockedknows Atray Dixit · together at Broad Institute (overlapped)
×4knows the team · via Broad Institute
×2knows the team · via Massachusetts Institute of Technology
×3knows the team · via Ginkgo Bioworks
knows the team · via Bellicum Pharmaceuticals, Inc.
knows the team · via University of St. Thomas
Oncko develops machine learning and experimental platforms to discover optimized multi-drug cancer treatment combinations by screening against resistance mechanisms. The company serves oncology drug developers seeking to identify efficacious combination regimens for cancer indications.
Founders & leadership
AD
Atray DixitinCo-founder, CEOHe earned a PhD during which he co-developed Perturb-seq with Aviv Regev, and previously founded Coral Genomics, an autoimmune diagnostics company acquired by Gordian Biotechnologies, where he held the role of VP of Technology.
BG
Bill GrossmaninCo-founder, Strategic AdvisorBill Grossman holds an M.D. and Ph.D. in Immunology from Washington University School of Medicine and has held senior clinical and medical leadership roles across the biopharmaceutical industry, including Chief Medical Officer positions at Arcus Biosciences and Bellicum Pharmaceuticals, Senior Vice President of Oncology at Gilead, and Global Group Medical Director for Cancer Immunotherapy at Genentech where he led clinical development of immunotherapy programs. He previously served on faculty at the Medical College of Wisconsin and Children's Hospital of Wisconsin.
Investors · 3
Competitors · 7
by search overlap
Oncusp Therapeutics6 shared keywordsOnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.
Oncosenx5 shared keywordsOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
OncoC44 shared keywordsOncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders. It advances its pipeline through internal R&D and external partnerships, including a collaboration with BioNTech to develop and commercialize gotistobart.
Onkure Therapeutics Inc4 shared keywordsOnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
Oncohealth4 shared keywordsOncoHealth develops software and services to help health plans, employers, and oncologists manage cancer care and reduce treatment complexity. The platform combines oncology management tools with nursing, mental health, nutrition, and navigation services for patients and health systems.
Octant Bio4 shared keywordsOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Onc4 shared keywordsOnc.AI develops the Onclara platform, which uses oncology real-world data to build predictive and prognostic AI models for cancer decision-making. Its products serve pharma companies with Phase IB/II clinical trial decisions and predict immunotherapy response and outcomes for metastatic lung cancer patients.
Companies competing with Oncko for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Oncko do?
- Oncko develops machine learning and experimental platforms to discover optimized multi-drug cancer treatment combinations by screening against resistance mechanisms. The company serves oncology drug developers seeking to identify efficacious combination regimens for cancer indications.
- Who founded Oncko?
- Oncko was founded by Atray Dixit, Bill Grossman.
- Who are Oncko's investors?
- Oncko's investors include Adverb Ventures, Illumina Ventures, Tenmile.